Assignment On

Sonear Laboratories LTD

Course Name: Pharmaceutical Technology-III
Course Code: BPH-412

Submitted To
Md. Mizanur Rahman
Assistant Professor
Department of Pharmacy
Faculty of Allied Health Science
Daffodil International University

Submitted By
Name: MD Rifat Ahmed Tanvir
ID: 201-29-399
Section: 23(B)
Department of Pharmacy
Daffodil International University

Date of Submission: 03/06/2023

 History
Sonear Laboratories Ltd that still produces Medicines in mass
production. The factory building is from the 70's so it might look old,
but the actual factory interior is much cleaner than many other
modern factories. The factory used to produce a lot of products before
the 2010 year mark such as tea product, massive number of medicines
and so on and now has decreased its production rate due to the
massive change in business structure of the modern era. The factory is
still present in the same location producing state wide recognized and
genuine medicines which have no other chemical problems in them.

Address
Factory: 11, 3-4 Toyenbee Circular Road, Dhaka 1000
Head Office: 11, 3-4 Toyenbee Circular Road, Dhaka 1000

Managing Director:
M.A. Obaidah.
Sonear laboratories ltd.
 Dosage form Manufacture

Sonear Laboratories Ltd.

OTC
Image Dosages Name Company Prescription

Orasol
Oral 10 gm + 750 gm + 1.75 gm + 1.45 gm/500 ml Sonear Prescription
Saline Dextrose Anhydrous + Potassium Chloride + Laboratories Ltd. Medicine
Sodium Chloride + Trisodium Citrate

Ranitab 150 Sonear

Tablet 150 mg OTC Medicine
Laboratories Ltd.
Ranitidine

Adlock 40 Sonear Prescription

Tablet 40 mg Laboratories Ltd. Medicine
Propranolol Hydrochloride

Adlock 10 Sonear Prescription

Tablet 10 mg Laboratories Ltd. Medicine
Propranolol Hydrochloride

Emitab Sonear Prescription

Tablet 5 mg Laboratories Ltd. Medicine
Prochlorperazine Maleate

Pentab 250 Sonear Prescription

Tablet 250 mg Laboratories Ltd. Medicine
Phenoxymethyl Penicillin

Pefla Sonear Prescription

Tablet 400 mg Laboratories Ltd. Medicine
Pefloxacin

Seridol Sonear
Tablet 500 mg OTC Medicine
Laboratories Ltd.
Paracetamol

Nida 400 Sonear Prescription

Tablet 400 mg Laboratories Ltd. Medicine
Metronidazole
 OTC
Image Dosages Name Company Prescription

Halotab L 50 Sonear Prescription

Tablet 50 mg Laboratories Ltd. Medicine
Halazone

Halotab 7.5 Sonear Prescription

Tablet 7.5 mg Laboratories Ltd. Medicine
Halazone

Halotab 15 Sonear Prescription

Tablet 15 mg Laboratories Ltd. Medicine
Halazone

Seren Sonear Prescription

Capsule 20 mg Laboratories Ltd. Medicine
Fluoxetine

Cloxafu 500 Sonear Prescription

Capsule 500 mg Laboratories Ltd. Medicine
Flucloxacillin

Cloxafu 250 Sonear Prescription

Capsule 250 mg Laboratories Ltd. Medicine
Flucloxacillin

Nacid 20 Sonear
Tablet 20 mg OTC Medicine
Laboratories Ltd.
Famotidine

Relaxen 5 Sonear Prescription

Tablet 5 mg Laboratories Ltd. Medicine
Diazepam

Cyclox 500 Sonear Prescription

Capsule 500 mg Laboratories Ltd. Medicine
Cloxacillin

Keprad 500 Sonear Prescription

Capsule 500 mg Laboratories Ltd. Medicine
Cephradine

Prescription
Keprad 250 Sonear Medicine
Capsule 250 mg Laboratories Ltd.
Cephradine
 1. Adlock 10
10 mg
Propranolol Hydrochloride

Indication
HTN, Cardiac arrhythmias, Myocardial infarction, Angina pectoris,
Portal hypertension, Migraine prophylaxis, Phaeochromocytoma,
Hyperthyroidism, Essential tremor
Administration
Tab: Should be taken on an empty stomach. Take before meals. Cap:
May be taken with or without food. Take consistently either always
w/ or always w/o meals.
Adult Dose
Oral Hypertension As conventional tab or oral soln: Initially, 40-80
mg bid. Usual range: 160-320 mg/day. Max: 640 mg/day. As
extended release cap: Initially, 80 mg once daily. Usual range: 120-
160 mg once daily. Max: 640 mg/day. Phaeochromocytoma As
conventional tab or oral soln: 60 mg/day in divided doses given 3
days pre-op w/ alpha-blocker. If tumour is inoperable, 30 mg/day in
divided doses may be given. Myocardial infarction As conventional
tab or oral soln: 40 mg 4 times daily for 2-3 days followed by 80 mg
bid. Alternatively, 180-240 mg/day in divided doses. Doses are given
w/in 5-21 days of MI. Cardiac arrhythmias Adult: As conventional tab
or oral soln: 30-160 mg/day in divided doses. Prophylaxis of migraine
As conventional tab or oral soln: Initially, 40 mg bid or tid. Usual
range: 120-240 mg/day. As extended release cap: 80 mg once daily,
may be increased to 160 mg once daily. Max: 240 mg/day. Portal
hypertension As conventional tab or oral soln: Initially, 40 mg bid
increased at wkly intervals up to 160 mg bid. As extended release cap:
80 mg once daily, may be increased to 160 mg once daily. Max: 320
mg once daily. Angina pectoris As conventional tab or oral soln:
Initially, 40 mg bid or tid. Usual range: 120-240 mg/day. Max: 320
mg/day. As extended release cap: 80 mg once daily, may be increased
to 160 mg once daily. Max: 240 mg/day. Hypertrophic
cardiomyopathy Adult: As conventional tab or oral soln: 10-40 mg, 3-
4 times daily. Hyperthyroidism As conventional tab or oral soln: 10-
40 mg, 3-4 times daily. As extended release cap: 80 mg once daily,
may be increased to 160 mg once daily. Max: 240 mg/day. Anxiety
As conventional tab or oral soln: 10-40 mg bid or tid. As extended
release cap: 80 mg once daily. Max: 160 mg once daily. Essential
tremor As conventional tab or oral soln: Initially, 40 mg bid or tid.
Usual range: 120-240 mg/day. As extended release cap: 80 mg once
daily, may be increased to 160 mg once daily. Max: 240 mg/day.
Hepatic impairment: Severe: 20 mg tid. As extended release cap: 80
mg once daily or 160 mg every other day.
Child Dose
Oral Hypertension Child: As conventional tab: Initially, 1 mg/kg/day
in 2 divided doses. Usual range: 2-4 mg/kg/day in 2 divided doses.
Max: 4 mg/kg/day in 2 or 3 divided doses. Phaeochromocytoma
Child: As conventional tab or oral soln: 0.25-0.5 mg/kg 3-4 times
daily. Cardiac arrhythmias Child: As conventional tab or oral soln:
0.25-0.5 mg/kg 3-4 times daily. Prophylaxis of migraine Child: As
conventional tab or oral soln: ?12 yr 10-20 mg bid or tid. >12 yr
Initially, 40 mg bid or tid increased to wkly intervals up to 160
mg/day. Max: 240 mg/day. Hyperthyroidism Child: As conventional
tab or oral soln: 0.25-0.5 mg/kg 3-4 times daily.
Contraindication
Sinus bradycardia, cardiogenic shock, sick sinus syndrome, Raynaud's
syndrome, 2nd and 3rd degree heart block, overt CHF, bronchial
asthma, COPD, untreated phaeochromocytoma, Prinzmetal's angina;
severe peripheral arterial disease, metabolic acidosis. Concomitant
use w/ thioridazine.
Mode of Action
Propranolol is a non-cardioselective beta-blocker that competitively
blocks beta1- and beta2-receptors resulting in decreased heart rate,
myocardial contractility, BP and myocardial oxygen demand. It has
membrane-stabilising properties.
Precaution
Sinus node dysfunction, DM, history of nonallergic bronchospasm
(e.g. chronic bronchitis, emphysema), myasthenia gravis, 1st degree
heart block. May mask signs of hyperthyroidism and hypoglycaemia.
Renal or hepatic impairment. Abrupt withdrawal may exacerbate
angina symptoms or precipitate MI in patients w/ coronary artery
disease. Elderly. Pregnancy and lactation. Patient Counselling Avoid
cigarette smoking. Monitoring Parameters Monitor ECG, heart rate
and BP.
Side Effect
Most adverse effects have been mild and transient and have rarely
required the withdrawal of therapy. Cardiovascular: Bradycardia;
congestive heart failure; intensification of AV block; hypotension;
paresthesia of hands; thrombocytopenic purpura; arterial
insufficiency, usually of the Raynaud type. Central Nervous System:
Lightheadedness; mental depression manifested by insomnia,
lassitude, weakness, fatigue; reversible mental depression progressing
to catatonia; visual disturbances; hallucinations; vivid dreams; an
acute reversible syndrome characterized by disorientation for time and
place, short-term memory loss, emotional lability, slightly clouded
sensorium, and decreased performance on neuropsychometrics. For
immediate formulations, fatigue, lethargy, and vivid dreams appear
dose related. Gastrointestinal: Nausea, vomiting, epigastric distress,
abdominal cramping, diarrhea, constipation, mesenteric arterial
thrombosis, and ischemic colitis. Allergic: Hypersensitivity reactions,
including anaphylactic/anaphylactoid reactions, pharyngitis and
agranulocytosis, erythematous rash, fever combined with aching and
sore throat, laryngospasm, and respiratory distress. Respiratory:
Bronchospasm. Hematologic: Agranulocytosis, nonthrombocytopenic
purpura, and thrombocytopenic purpura. Skin: Stevens-Johnson
Syndrome, toxic epidermal necrolysis, exfoliative dermatitis,
erythema multiforme, and urticaria.
Pregnancy Category Note
Pregnancy category: C, D in 2nd & 3rd trimesters.
Interaction
May cause additive negative chronotropic and/or inotropic effect w/
amiodarone, disopyramide, quinidine, flecainide and Ca channel
blockers. May cause additive hypotensive effect w/ phenothiazines. β-
adrenergic stimulating effects of sympathomimetic agents are
antagonised. Concomitant admin w/ catecholamine-depleting drugs
(e.g. reserpine) may cause additive effects and potentiate depression.
Reduced antihypertensive effect w/ aluminium and NSAIDs.
Coadministration w/ warfarin increases its bioavailability and
prothrombin time. Altered antidiabetic response when used w/
antidiabetic agents and insulin. Increased risk of hypotension and
attenuation of the reflex tachycardia w/ anaesth drugs. Potentially
Fatal: Increased risk of QT interval prolongation and torsades de
pointes w/ thioridazine.
 2. Orasol
10 gm + 750 gm + 1.75 gm + 1.45 gm/500 ml
Dextrose Anhydrous + Potassium Chloride + Sodium Chloride + Trisodium Citrate

Indication
Diarrhea, Dehydration, Vomiting, Fluid and Electrolytes imbalance
Adult Dose
Adult: After each loose stool or vomiting 200-400 ml of prepared
saline. Daily dose should be equivalent to patients' fluid requirement
for maintenance and replenishment of losses. During saline therapy
normal food should be continued in case of adults.
Child Dose
Children above 10 years: After each loose stool or vomiting 200-400
ml of prepared saline. Children 2 to 10 years: After each loose stool
or vomiting 100-200 ml of prepared oral saline. Children less than 2
years: After each loose stool or vomiting 10 to 20 spoonful (50-100
ml) of prepared saline. Daily dose should be equivalent to patients'
fluid requirement for maintenance and replenishment of losses.
During saline therapy mother should not stop breast-feeding to their
child.
Contraindication
Patients with known hypersensitivity.
Mode of Action
Potassium chloride is a major cation of the intracellular fluid. It plays
an active role in the conduction of nerve impulses in the heart, brain
and skeletal muscle; contraction of cardiac skeletal and smooth
muscles; maintenance of normal renal function, acid-base balance,
carbohydrate metabolism and gastric secretion. Sodium chloride is the
major extracellular cation. It is important in electrolyte and fluid
balance, osmotic pressure control and water distribution as it restores
sodium ions. It is used as a source of electrolytes and water for
hydration, treatment of metabolic acidosis, priming solution in
haemodialysis and treatment of hyperosmolar diabetes. It is also used
as diluents for infusion of compatible drug additives. Dextrose is a
monosaccharide that is used as a source of calories and water for
hydration. It helps to reduce loss of body protein and nitrogen. It also
promotes glycogen deposition in the liver. When used with insulin, it
stimulates the uptake of potassium by cells, especially in muscle
tissue, thus lowering serum potassium levels.
Precaution
Depressed renal function, severe continuing diarrhoea or other critical
fluid losses may need supplementation with parenteral fluids along
with oral saline. Reconstitue saline should be used within 6 hours.
Side Effect
No significant side effects.
3. Seren
20 mg
Fluoxetine

Indication
Panic disorder, Obsessive compulsive disorder, Trichotillomania,
Premenstrual dysphoric disorder, Major depression, Post-traumatic
stress disorder, Bulimia nervosa, Body dysmorphic disorder, Binge
eating disorder
Administration
May be taken with or without food.
Adult Dose
Oral Depression Adult: Initially, 20 mg once daily. May gradually
increase up to max 80 mg daily in 2 divided doses, if no clinical
response after several wk. Bulimia nervosa Adult: 60 mg daily as a
single or in divided doses. Hepatic impairment: Reduce dose and/or
dosing frequency. Obsessive compulsive disorder Adult: Initially, 20
mg once daily, increased up to 60 mg daily if no clinical response
after several wk. Max: 80 mg daily in 2 divided doses.
Child Dose
Oral Depression Child: >8 yr Initially, 10 mg daily, may increase to
20 mg daily after 1-2 wk. Low wt childn: Initially, 10 mg daily, may
increase to 20 mg daily after several wk, only if clinical response is
insufficient. Obsessive compulsive disorder Child: >7 yr Initially, 10
mg daily, may increase to 20 mg daily after 2 wk; increase further up
to 60 mg daily after several wk as necessary. Low-wt childn: Initially,
10 mg daily, may increase to 20-30 mg daily after several wk, if
required.
Renal Dose
Renal impairment: Use caution; drug accumulation may occur with
severe renal impairment
Contraindication
Severe renal or hepatic failure; hypersensitivity; lactation;
concomitant MAOIs or within 2 wk of MAOI withdrawal.
Mode of Action
Fluoxetine is a potent and highly selective inhibitor of serotonin (5-
HT) re-uptake. No affinity for adrenoceptors or histamine, GABA-B,
or muscarinic receptors.
Precaution
Unstable epilepsy, liver and renal impairment, cardiac disease,
diabetes, electroconvulsive therapy, bleeding disorders, closed-angle
glaucoma; pregnancy. May impair performace of skilled tasks;
withdraw gradually. Close monitoring of clinical worsening and
behavioural changes during the 1st few mth of treatment or when
there are dose changes. Lactation Excreted in milk; avoid (AAP states
effect on nursing infants is unknown but may be of concern)
Side Effect
>10% Headache (20-25%),Nausea (12-29%),Insomnia (10-
33%),Anorexia (4-17%),Anxiety (6-15%),Asthenia (10-
15%),Diarrhea (8-18%),Nervousness (8-14%),Somnolence (5-
17%),Tremor (3-13%),Weakness (7-21%) 1-10% Dizziness (9%),Dry
mouth (6-10%),Dyspepsia (6-10%),Sweating (5-10%),Decreased
libido (2-5%),Abnormal taste (>1%),Agitation (>1%),Chest pain
(>1%),Chills (>1%),Confusion (>1%),Ear pain (>1%),Hypertension
(>1%),Increased appetite (>1%),Palpitation (>1%),Sleep disorder
(>1%),Tinnitus (>1%),Urinary frequency (>1%),Vomiting
(>1%),Weight gain (>1%) Frequency Not Defined Dysglycemia in
patients with DM Risk of seizure with concomitant electroconvulsive
therapy (rare) Potentially Fatal: Rarely, systemic events possibly
related to vasculitis have been reported in patients with rash but may
be serious involving lungs, kidney and liver.
Pregnancy Category Note
Pregnancy category: C Treatment of pregnant women during the first
trimester: There are no adequate and well-controlled clinical studies
on the use of fluoxetine in pregnant women, but 1 prospective cohort
study conducted by the European Network of Teratology Information
Services reported an increased risk of cardiovascular malformations in
infants born to women (N = 253) exposed to fluoxetine during the
first trimester of pregnancy, compared with infants of women (N =
1359) who were not exposed to fluoxetine Use late in the third
trimester associated with complications in newborns and may require
prolonged hospitalization, respiratory support, and tube feeding When
treating a pregnant woman with fluoxetine, physician should carefully
consider trimester both for the potential risks of taking an SSRI, along
with the established benefits of treating depression with an
antidepressant; the decision can only be made on a case by case basis
Lactation Excreted in milk; avoid (AAP states effect on nursing
infants is unknown but may be of concern)
Interaction
May cause transient shift in plasma conc of tightly protein bound
drugs e.g. warfarin and digoxin, resulting in adverse effects. T1/2 of
diazepam is prolonged. Avoid concurrent use with clopidogrel.
Potentially Fatal: Serious reactions when combined with MAOIs; at
least 14 days should elapse after MAOIs withdrawal before starting
fluoxetine treatment or at least 5 wk should elapse after fluoxetine
treatment before starting MAOIs therapy.

Thank You